# CADTH

### Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:

Carolyn Nessim

Name of drug and indication under review:

Pembrolizumab in the adjuvant setting for melanoma

### **Conflict of Interest Declaration**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- · affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

### Section A: Payment Received

- 1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?
  - ⊠ Yes
  - 🗆 No

If no, please go to Section B.

2. What form of payment did you receive? (Check all that apply.)

<ul> <li>Advisory role (e.g., advisory boards, health technology assessment submission advice)</li> </ul>	<ul> <li>Program or Operating Funding (e.g., website)</li> </ul>
Conference attendance	Research/educational grants
□ Royalties	□ Travel grants
□ Gifts	Sponsorship of events
Honoraria	□ Other, please specify:

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

Merck in collaboration with BMS and Novartis sponsor our Melanoma Communities of Practice. We have 4 meetings a year that they pay for. I do not know the amount, they share the cost and they do not tell me how much it is. The meeting is often attende by 25-35 people in a restaurant setting. The communities of practice gathers all clinicians in the region to discuss quality improvements for melanoma patients in our region. We discuss all topics from pathology to imaging to surgical management and medical management. We survey members at each meeting and they have never responded that they feel there is commercial bias in our meeting.

Merck also sponsors our Multidisciplinary Surgical Oncology Journal Club. We have 4 meetings a year where we discuss the latest and most up to date publications in Surgical Oncology. We actually discuss a variety of topics often unrelated to

# CADTH

immunotherapy. These include surgical trials in breast, colorectal, sarcoma, gastric and skin cancers as well as chemotherapy and radiation trials etc. We have reviewed some immunotherapy trials including those about competitive agents. We have surveyed the trainees and they have never felt commercial bias in the meetings. They have not told me the amount they spend o these meetings. The meeting is attended by 15-20 people in a restaurant setting.

# CADTH

### Section B: Holdings or Other Interests

Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

No

### Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

2018/12/21 Carolyn Nessim C Name Signature

Clinician	Input	Template fo	r CADTH	pan-Canadian	Oncology	Drug	Review	Program
omnonom	mpore	rompiato io	0/10/11	pan oanaanan	oncoiog,	Diug	11011011	riogram



### pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

CADTH

DCODR PAN-CANADIAN ONCOLOGY DRUG REVIEW

Name of registered clinician: Frances Wright

Name of drug and indication under review: pembrotizumab/metanoma

### **Conflict of Interest Declarations**

proceeding the subject with a conditional bill its effective a Cool of influencing the information submitted. Conflict of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

### Section A: Payment Received

 Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
 ✓ Yes
 □ No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, HTA submission advice)
  - Conference attendance
  - Royalties
  - Gifts
  - Honoraria
  - Other, please specify: Click here to enter text.
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Click here to enter text. Roche - entre research grant neo adjus ant BRAFIMEN inhibitor for clinically node positive malaon Board - 5 EMD-Serano (Avelumab) - 2 yrs pCODR Clinician Input on a Drug Review © February 2016 CADTH pCODR | PAN CANADIAN ONCOLOGY DRUG REVIEW

Program or Operating Funding

Research/educational grants

Sponsorship of Events

(e.g., website)

Travel grants

## CADT

Before completing this template, be sure to register with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

#### Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below. NO

Click here to enter text.

### Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below. NO

Click here to enter text.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:	Click here I	to ente
Dale.	CIICK HEIE I	o ente

Name: Click here to enter text.

Signature: Click here to enter text.

er text. 2013 83 Frances wright

2



Program or Operating Funding

Research/educational grants

Sponsorship of Events

(e.g., website)

Travel grants

Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

### pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Marcus Butler

Name of drug and indication under review: pembrolizumab/melanoma

### **Conflict of Interest Declarations**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

### Section A: Payment Received

 Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
 ☑ Yes
 □ No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, HTA submission advice)
  - Conference attendance
  - Royalties
  - ☐ Gifts
  - Honoraria
  - Other, please specify: Presentations to industry
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

 $\boxtimes$ 

 $\boxtimes$ 

Bristol-Myers Squibb (BMS): Advisory Boards: (\$ 100 in 2015; \$ 100 in 2016) Merck: Advisory Boards: (\$ 100 in 2015; \$ 100 in 2016)

## Merck Educational Programs: Merck Supported Ad Boards (\$ in 2015); Merck Supported Education (\$ in 2015; \$ in 2016);

BMS Supported Education: (\$ in 2015)



Before completing this template, be sure to register with the pCODR program. Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

Novartis: Advisory Boards (\$ in 2015; \$ in 2016) Novartis Presentations: (\$ in 2016) Immunocore: Advisory Board (\$ US in 2016) Immunovaccine: Advisory Board (\$ in 2015) EMD Serono: Advisory Board (\$ in 2016)

### **Section B: Holdings or Other Interests**

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

none

### Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below. none

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: 13 November 2018

Marcus Butler Name:

Main Sith

Signature:

pCODR Clinician Input on a Drug Review © February 2016 CADTH-pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW

Before completing this template, be sure to register with the pCODR program. Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

### pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr Tara Baetz

Name of drug and indication under review: Nivolumab/Melanoma

### **Conflict of Interest Declarations**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

### Section A: Payment Received


1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? X Yes 

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards,  $\mathbf{X}$ HTA submission advice)
  - Conference attendance
  - Royalties
  - Gifts
  - X Honoraria
  - Other, please specify: Click here to enter text
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.
  - Bristol Myers Squibb honoraria for giving educational talks
  - Merck advisory board role (not all for melanoma indications)

#### (e.g., website) Research/educational grants

- Travel grants
- Sponsorship of Events



CADTH **PAN-CANADIAN** ONCOLOGY DRUG REVIEW

# CADTH POR PAN CANADIAN ONCOLOGY DRUG HE VIE W

Before completing this template, be sure to register with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

Section B: Holdings or Other Interests Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: November 14, 2017

Name:

Signature:

Tara Baetz Alente te



Program or Operating Funding

Research/educational grants

Sponsorship of Events

(e.g., website)

Travel grants

Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

### pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Teresa Petrella

Name of drug and indication under review: Pembrolizumab/melanoma

### **Conflict of Interest Declarations**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

### **Section A: Payment Received**

 Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
 ☑ Yes
 □ No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
  - Advisory role (e.g., advisory boards, HTA submission advice)
  - □ Conference attendance
  - □ Royalties
  - □ Gifts
  - 🛛 Honoraria
  - Other, please specify: Click here to enter text.

## 3. Please provide the names of companies and organizations and the amounts of the payments in <u>the box below</u>.

 $\square$ 

BMS \$



Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

### **Section B: Holdings or Other Interests**

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

No

#### Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below. No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: Nov 15, 2018

Name: Teresa Petrella

Altrik\_

Signature: